贝特里克萨班是一种广泛的抗病毒抑制剂,通过激活天生的免疫力来激活
Shiyu Hu1, Yang Zhao1, Xingyu Chen1
1Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, National Health Commission (NHC) Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China.
Frontiers in cellular and infection microbiology
|September 8, 2025
概括
贝特里克萨班 (BT) 激活天生的免疫系统,促进干扰素的产生,以对抗广泛的病毒感染. 这种新型化合物显示出广泛的抗病毒潜力,提供了一个有前途的新疗法途径.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 药理学 药理学 是一个学科.
背景情况:
- 天生的免疫系统对于控制病毒感染至关重要.
- I型干扰素 (IFN-I) 信号传递是抗病毒免疫的关键组成部分.
研究的目的:
- 识别具有广泛抗病毒活性的新型小分子化合物.
- 研究贝特里克萨班 (BT) 在先天性免疫激活和抗病毒防御中的作用机制.
主要方法:
- 在实验室中评估了BT对IFN-β产生和干扰素刺激基因 (ISG) 的影响.
- 测试了BT对多种病毒的抗病毒疗效,包括VSV,HSV-1,MHV-A59,EMCV和IAV.
- 研究了IRF3,Mx1和Mx2在BT介导抗病毒活性中的作用.
- 在体内使用感染VSV的野生类型小鼠评估BT的疗效和机制.
主要成果:
- BT治疗诱导了IFN-β的产生和上调的ISG,从而产生广泛的抗病毒作用.
- BT可以抑制VSV,HSV-1,MHV-A59,EMCV和IAV的复制.
- 抗病毒活性依赖于先天免疫激活,涉及IRF3,Mx1和Mx2.
- 在体内,BT诱导IFNB1表达,并抑制小鼠的病毒复制.
结论:
- 贝特里克萨班 (BT) 是先天免疫反应的强有力的激活剂,具有广泛的抗病毒特性.
- BT的机制涉及诱导I型干扰素信号通路.
- 作为一种抗病毒剂,BT显示出显著的治疗潜力.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:29Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
01:16Clot Retraction and Fibrinolysis
8.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
12.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.2K